Journal
CANCERS
Volume 14, Issue 6, Pages -Publisher
MDPI
DOI: 10.3390/cancers14061361
Keywords
biochemical recurrent prostate cancer; PSMA PET-CT; molecular imaging; recurrent prostate cancer; metastatic prostate cancer; conventional imaging
Categories
Ask authors/readers for more resources
Molecular imaging with PSMA PET-CT is more accurate and sensitive than conventional imaging, allowing for earlier diagnosis of advanced prostate cancer. However, overtreatment could be a concern. Understanding the continuum of disease and the accuracy of different imaging modalities is important for patient management.
Simple Summary Molecular imaging with PSMA PET-CT is more accurate and sensitive than conventional imaging with CT, MRI, and a Technetium-99 bone scan. This new imaging modality will result in more advanced disease being diagnosed earlier which may improve survival, however, it could also lead to overtreatment. Since molecular imaging has the potential to identify disease prior to its detection on conventional imaging, this highlights that advanced prostate cancer exists on a continuum. This review discusses how PSMA PET-CT can be used in managing prostate cancer using clinical scenarios. Conventional imaging has been the standard imaging modality for assessing prostate cancer recurrence and is utilized to determine treatment response to therapy. Molecular imaging with PSMA PET-CT has proven to be more accurate, sensitive, and specific at identifying pelvic or distant metastatic disease, resulting in earlier diagnosis of advanced disease. Since advanced disease may not be seen on conventional imaging, due to its lower sensitivity, but can be identified by molecular imaging, this reveals that metastatic prostate cancer occurs on a continuum from negative PSMA PET-CT and negative conventional imaging to positive PSMA PET-CT and positive conventional imaging. Understanding this continuum, the accuracy of these modalities, and treatment related outcomes based on imaging, will allow the clinician to counsel patients on management. This review will highlight the differences in conventional and molecular imaging in prostate cancer and how PSMA PET-CT can be used for the management of prostate cancer patients in different clinical scenarios, while providing cautionary notes for overtreatment.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available